copy;2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 28, 2010; 16(36): 4564-4569
Published online Sep 28, 2010. doi: 10.3748/wjg.v16.i36.4564
Published online Sep 28, 2010. doi: 10.3748/wjg.v16.i36.4564
Table 3 Medications taken by cases and controls
| Case (%) | Control (%) | P value | OR | 95% CI | |
| Antihypertensives | 51.5 | 41 | 0.023 | 1.595 | 1.067-2.383 |
| Beta-blockers | 5.6 | 5.6 | 1 | 1 | 0.443-2.26 |
| Ca2+ channel antagonists | 22.3 | 14.6 | 0.027 | 1.771 | 1.065-2.946 |
| ACE inhibitors | 27.3 | 18.3 | 0.018 | 1.776 | 1.102-2.861 |
| Nitrates | 10.5 | 9.3 | 0.67 | 1.143 | 0.617-2.117 |
| ARB | 1.2 | 4 | 0.109 | 0.358 | 0.102-1.259 |
| NSAIDs | 10.5 | 9.9 | 0.823 | 1.077 | 0.561-2.07 |
| Digoxin | 3.1 | 7.4 | 0.060 | 0.383 | 0.141-1.042 |
| Antidepressants | 3.7 | 6.2 | 0.222 | 0.540 | 0.201-1.453 |
| Diuretics | 26.1 | 26.1 | 1 | 1 | 0.656-1.525 |
| ASA | 31.6 | 18 | < 0.001 | 2.153 | 1.371-3.382 |
| Acenocumarol | 5.6 | 5.6 | 1 | 1 | 0.443-2.26 |
- Citation: Fernández JC, Calvo LN, Vázquez EG, García MJG, Pérez MTA, Silva IM, Seara JF. Risk factors associated with the development of ischemic colitis. World J Gastroenterol 2010; 16(36): 4564-4569
- URL: https://www.wjgnet.com/1007-9327/full/v16/i36/4564.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i36.4564